Alaunos Therapeutics, Inc. — Form 8-K Summary
Event date: October 5, 2026. The report was signed on October 9, 2026. This filing reports a Nasdaq listing-compliance matter, not periodic financial results.
Business context and financial position
Nasdaq notified the Company that it did not meet Listing Rule 5550(b)(1), which requires at least $2.5 million in stockholders’ equity for continued listing on the Nasdaq Capital Market. The filing provides no current financial statements or clear values for revenue, earnings, cash flow, margins, debt, liquidity, or stockholders’ equity.
Material development and management response
The Company had received an initial noncompliance notice on April 9, 2026, and submitted a plan to regain compliance. On October 5, Nasdaq notified the Company that its securities were subject to delisting. Alaunos plans to timely request a hearing before the Nasdaq Hearings Panel. A timely hearing request will stay further suspension or delisting action at least until the hearing and any extension granted by the Panel expires.
The Company is evaluating strategic alternatives and working with a financial advisor on potential transactions it believes could strengthen its financial position and help it regain compliance. No transaction is assured or reported as completed.
Risks and contingencies
- The Panel may not grant continued listing, and the Company may not demonstrate compliance within any extension period.
- The strategic-alternatives process may not produce a suitable alternative, definitive agreement, or completed transaction.
- Any transaction would depend on negotiations, due diligence, definitive agreements, approvals, and closing conditions.
- Even if completed, a transaction may not enable the Company to regain or maintain compliance or prevent trading suspension or delisting.
Key facts for investors to verify
- Whether the Company timely requests a hearing and the Panel’s decision and any extension granted.
- Whether the Company reports a specific plan or transaction that addresses the stockholders’ equity shortfall.
- Whether the Company subsequently demonstrates compliance with Nasdaq’s continued-listing requirements.